Paroxetine

Found 23 Sample Hits

m/z	Adducts	Species	Organ	Scanning	Sample
312.1367	[M+H-H2O]+ PPM:8.7	Homo sapiens	Liver	MALDI (DHB)	20171107_FIT4_DHBpos_p70_s50 - Rappez et al (2021) SpaceM reveals metabolic states of single cells Resolution: 50μm, 70x70 Description
329.1629	[M-H2O+NH4]+ PPM:9.3	Homo sapiens	esophagus	DESI ()	LNTO22_1_4 - MTBLS385 Resolution: 17μm, 82x80 Description
347.1716	[M+NH4]+ PPM:14.2	Homo sapiens	esophagus	DESI ()	LNTO22_1_4 - MTBLS385 Resolution: 17μm, 82x80 Description
329.1724	[M-H2O+NH4]+ PPM:19.5	Mus musculus	Liver	MALDI (CHCA)	Salmonella_final_pos_recal - MTBLS2671 Resolution: 17μm, 691x430 Description A more complete and holistic view on host–microbe interactions is needed to understand the physiological and cellular barriers that affect the efficacy of drug treatments and allow the discovery and development of new therapeutics. Here, we developed a multimodal imaging approach combining histopathology with mass spectrometry imaging (MSI) and same section imaging mass cytometry (IMC) to study the effects of Salmonella Typhimurium infection in the liver of a mouse model using the S. Typhimurium strains SL3261 and SL1344. This approach enables correlation of tissue morphology and specific cell phenotypes with molecular images of tissue metabolism. IMC revealed a marked increase in immune cell markers and localization in immune aggregates in infected tissues. A correlative computational method (network analysis) was deployed to find metabolic features associated with infection and revealed metabolic clusters of acetyl carnitines, as well as phosphatidylcholine and phosphatidylethanolamine plasmalogen species, which could be associated with pro-inflammatory immune cell types. By developing an IMC marker for the detection of Salmonella LPS, we were further able to identify and characterize those cell types which contained S. Typhimurium. [dataset] Nicole Strittmatter. Holistic Characterization of a Salmonella Typhimurium Infection Model Using Integrated Molecular Imaging, metabolights_dataset, V1; 2022. https://www.ebi.ac.uk/metabolights/MTBLS2671.
347.1733	[M+NH4]+ PPM:18.6	Mus musculus	Liver	MALDI (CHCA)	Salmonella_final_pos_recal - MTBLS2671 Resolution: 17μm, 691x430 Description A more complete and holistic view on host–microbe interactions is needed to understand the physiological and cellular barriers that affect the efficacy of drug treatments and allow the discovery and development of new therapeutics. Here, we developed a multimodal imaging approach combining histopathology with mass spectrometry imaging (MSI) and same section imaging mass cytometry (IMC) to study the effects of Salmonella Typhimurium infection in the liver of a mouse model using the S. Typhimurium strains SL3261 and SL1344. This approach enables correlation of tissue morphology and specific cell phenotypes with molecular images of tissue metabolism. IMC revealed a marked increase in immune cell markers and localization in immune aggregates in infected tissues. A correlative computational method (network analysis) was deployed to find metabolic features associated with infection and revealed metabolic clusters of acetyl carnitines, as well as phosphatidylcholine and phosphatidylethanolamine plasmalogen species, which could be associated with pro-inflammatory immune cell types. By developing an IMC marker for the detection of Salmonella LPS, we were further able to identify and characterize those cell types which contained S. Typhimurium. [dataset] Nicole Strittmatter. Holistic Characterization of a Salmonella Typhimurium Infection Model Using Integrated Molecular Imaging, metabolights_dataset, V1; 2022. https://www.ebi.ac.uk/metabolights/MTBLS2671.
368.2363	[M+K]+ PPM:11.3	Homo sapiens	esophagus	DESI ()	LNTO22_1_9 - MTBLS385 Resolution: 75μm, 89x74 Description
368.2356	[M+K]+ PPM:13.2	Homo sapiens	esophagus	DESI ()	LNTO30_8M_1 - MTBLS385 Resolution: 17μm, 69x54 Description
368.2293	[M+K]+ PPM:9.7	Homo sapiens	colorectal adenocarcinoma	DESI ()	520TopL, 490TopR, 510BottomL, 500BottomR-profile - MTBLS415 Resolution: 17μm, 147x131 Description The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024).
368.2362	[M+K]+ PPM:11.6	Homo sapiens	esophagus	DESI ()	LNTO26_7_1 - MTBLS385 Resolution: 17μm, 75x74 Description
368.2366	[M+K]+ PPM:10.5	Homo sapiens	esophagus	DESI ()	LNTO26_7_2 - MTBLS385 Resolution: 17μm, 135x101 Description
368.236	[M+K]+ PPM:12.1	Homo sapiens	esophagus	DESI ()	LNTO26_7_3 - MTBLS385 Resolution: 75μm, 82x88 Description
368.2373	[M+K]+ PPM:8.6	Homo sapiens	esophagus	DESI ()	TO40T - MTBLS385 Resolution: 17μm, 82x74 Description
368.2353	[M+K]+ PPM:14	Homo sapiens	esophagus	DESI ()	TO29T - MTBLS385 Resolution: 75μm, 56x48 Description
368.2356	[M+K]+ PPM:13.2	Homo sapiens	esophagus	DESI ()	TO41T - MTBLS385 Resolution: 75μm, 69x43 Description
368.2354	[M+K]+ PPM:13.8	Homo sapiens	esophagus	DESI ()	LNTO30_8M_2 - MTBLS385 Resolution: 75μm, 108x68 Description
368.2355	[M+K]+ PPM:13.5	Homo sapiens	esophagus	DESI ()	LNTO30_8M_3 - MTBLS385 Resolution: 75μm, 69x54 Description
368.2359	[M+K]+ PPM:12.4	Homo sapiens	esophagus	DESI ()	LNTO30_8M_4 - MTBLS385 Resolution: 75μm, 62x48 Description
368.2358	[M+K]+ PPM:12.7	Homo sapiens	esophagus	DESI ()	LNTO30_8M_5 - MTBLS385 Resolution: 75μm, 56x54 Description
368.2352	[M+K]+ PPM:14.3	Homo sapiens	esophagus	DESI ()	LNTO30_17_2 - MTBLS385 Resolution: 75μm, 82x54 Description
368.2359	[M+K]+ PPM:12.4	Homo sapiens	esophagus	DESI ()	LNTO22_1_7 - MTBLS385 Resolution: 75μm, 69x54 Description
368.2362	[M+K]+ PPM:11.6	Homo sapiens	esophagus	DESI ()	LNTO26_16_1 - MTBLS385 Resolution: 75μm, 95x88 Description
368.2357	[M+K]+ PPM:12.9	Homo sapiens	esophagus	DESI ()	LNTO30_7_1 - MTBLS385 Resolution: 75μm, 69x68 Description
329.1655	[M-H2O+NH4]+ PPM:1.4	Homo sapiens	colorectal adenocarcinoma	DESI ()	240TopL, 210TopR, 230BottomL, 220BottomR-centroid - MTBLS176 Resolution: 50μm, 142x141 Description

Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D₂ or histamine H₁ receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT_1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT_1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation. D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065690 - Cytochrome P-450 CYP2D6 Inhibitors N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants > N06AB - Selective serotonin reuptake inhibitors D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C94725 - Selective Serotonin Reuptake Inhibitor D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent CONFIDENCE standard compound; INTERNAL_ID 8555 CONFIDENCE standard compound; INTERNAL_ID 1526 D049990 - Membrane Transport Modulators Paroxetine, a phenylpiperidine derivative, is a potent and selective serotonin reuptake inhibitor (SSRI). Paroxetine is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs[1].